Brawertia veronii for treating irritable bowel syndrome and application of Brawertia veronii for treating irritable bowel syndrome

Abstract

The invention discloses a Brawertia wevidii for treating irritable bowel syndrome and application thereof, and belongs to the technical field of microorganisms. According to the present invention, the bacterial strain is Blauraceae wettingii (Blauraceae wettingii) MW-022, and the preservation number of the bacterial strain is GDMCC No: 66940; experiments prove that the strain has the effect of improving the symptoms of the irritable bowel syndrome, the weight loss of a mouse with the irritable bowel syndrome is delayed, the visceral sensitivity is remarkably reduced, the time for first-time defecation is delayed, low-grade inflammation is inhibited, oxidative stress is relieved, and meanwhile affective disorder of the mouse is relieved; the irritable bowel syndrome can be effectively treated by independently using the traditional Chinese medicine composition.

Description

A strain of *Brutella vesiculosus* for the treatment of irritable bowel syndrome and its application Technical Field

[0001] This invention belongs to the field of microbial technology, and in particular relates to a strain of *Brutella westermani* for treating irritable bowel syndrome and its application. Background Technology

[0002] Irritable bowel syndrome (IBS) is a common chronic gastrointestinal dysfunction characterized by recurrent episodes of abdominal pain and changes in bowel habits (such as diarrhea, constipation, or alternating episodes of both), without any underlying organic lesion to explain the symptoms. According to the Rome criteria, IBS can be classified into diarrhea-predominant, constipation-predominant, mixed, and undetermined types. The pathophysiological mechanisms of IBS are complex, involving the interaction of multiple factors, currently recognized as including visceral hypersensitivity, gastrointestinal motility disorders, gut microbiota dysbiosis, low-grade intestinal mucosal inflammation, impaired intestinal barrier function, and dysfunction of the brain-gut axis. These abnormalities not only lead to typical gastrointestinal symptoms but are also often accompanied by mood disorders such as anxiety and depression, significantly reducing patients' quality of life and placing a continuous burden on the social healthcare system.

[0003] The clinical treatment of irritable bowel syndrome (IBS) currently faces significant challenges. First-line drugs such as antispasmodics, antidiarrheals, and laxatives can provide short-term relief of specific symptoms, but they generally suffer from significant side effects and limited target specificity. Antispasmodics often cause anticholinergic reactions such as dry mouth and dizziness; long-term use of antidiarrheals can easily lead to constipation and drug dependence. More importantly, these traditional drugs are difficult to effectively address the core pathological aspects of IBS, including low-grade intestinal inflammation and abnormal brain-gut axis regulation, and have limited effects on improving accompanying mood disorders. Due to concerns about the safety of chemical drugs, more and more patients are opting for natural therapies such as probiotics. However, common probiotic preparations have limitations such as high strain specificity, unstable efficacy, and insufficient potency, making it difficult to achieve the efficacy levels required for drug therapy. Therefore, this study aims to overcome the current treatment dilemma by systematically screening and validating a specific strain that can achieve the efficacy levels of conventional drugs in improving core symptoms while retaining the natural safety advantages of probiotics, thus providing a more ideal treatment option for IBS patients.

[0004] Brontë westerlensis is an important commensal bacterium in the human gut, playing a crucial role in maintaining intestinal barrier integrity, regulating immune responses, and suppressing inflammation. Clinical observations have revealed a characteristic reduction of this bacterium in the intestines of patients with irritable bowel syndrome (IBS), suggesting that dysbiosis may be related to the disease's development. However, current research primarily focuses on the bacterium's metabolic functions and ecological characteristics; there is no systematic evidence to clarify its value as a standalone agent in the prevention or treatment of IBS, and there is also a lack of research on the development of targeted strain formulations and its mechanism of action. Summary of the Invention

[0005] In view of this, the present invention aims to provide the use of *Brutella westermani* in the preparation of pharmaceutical or probiotic formulations for the prevention or treatment of irritable bowel syndrome (IBS). This *Brutella westermani* can delay weight loss in IBS mice, significantly reduce visceral sensitivity, delay the first loose stool, suppress low-grade inflammation, alleviate oxidative stress, and reduce emotional disturbances in mice. It can effectively treat IBS when used alone. Furthermore, it combines high safety with therapeutic efficacy, providing an innovative microecological treatment option for IBS.

[0006] The *Blautia wexlerae* MW-022 described in this invention is deposited at the Guangzhou Microbial Culture Collection Center, with accession number GDMCC No: 66940.

[0007] The present invention provides a microbial preparation containing the aforementioned Brontë MW-022.

[0008] In one embodiment, the bacterial count of *Brutella vesicae* MW-022 in the microbial preparation is not less than 1 × 10⁻⁶. 5 CFU / mL or 1×10 5 CFU / g.

[0009] The present invention provides a pharmaceutical product containing the aforementioned Brontë MW-022 or the aforementioned microbial preparation.

[0010] Preferably, the drug can improve weight loss caused by modeling.

[0011] Preferably, the drug can delay the time of the first loose stool.

[0012] Preferably, the drug can reduce the increase in visceral sensitivity caused by modeling.

[0013] Preferably, the drug can inhibit inflammation.

[0014] Preferably, the drug is capable of regulating oxidative stress.

[0015] Preferably, the drug can regulate mood disorders.

[0016] In one embodiment, the dosage form of the drug includes solid dosage forms, liquid dosage forms, or semi-solid dosage forms; the solid dosage forms include tablets, capsules, granules, micro-pellets, or powders; the liquid dosage forms include solutions, suspensions, or drops.

[0017] Preferably, the dosage form of the drug also includes preparations processed by special processes, including lyophilized powder injections, microcapsules, enteric-coated preparations, or sustained-release preparations.

[0018] Preferably, the content of *Brutella vesicae* MW-022 in the drug is 1×10⁻⁶. 5 CFU / mL ~ 1×10 10 CFU / mL or 1×10 5 CFU / g ~ 1×10 10 CFU / g.

[0019] Preferably, the drug also includes a pharmaceutically acceptable carrier.

[0020] Preferably, the pharmaceutically acceptable carrier is selected from at least one of the following: dispersion medium, flow aid, release regulator, matrix forming agent, taste improver, microbial growth factor, pH stabilizer, encapsulating agent, antioxidant or cryoprotectant.

[0021] The present invention also provides the use of the aforementioned *Blaubursella vesicatoria* MW-022 or the aforementioned microbial preparation in the preparation of medicaments for the prevention and / or treatment of irritable bowel syndrome.

[0022] In one embodiment, the drug has at least one of the following functions: (1) slowing down weight loss; (2) regulating the frequency and characteristics of defecation; (3) reducing visceral hypersensitivity; (4) inhibiting low-grade intestinal inflammation; (5) regulating oxidative stress; and (6) alleviating anxiety-like behavior.

[0023] Beneficial effects of the present invention: The present invention relates to the use of *Brutella brevis* MW-022 in the preparation of drugs or probiotic preparations for the prevention and / or treatment of irritable bowel syndrome (IBS). Experiments show that this strain can significantly alleviate weight loss in model animals, delay the time of first loose stool passage, reduce visceral hypersensitivity, inhibit intestinal inflammatory response, regulate oxidative stress, and improve related mood disorders, thus exerting a comprehensive therapeutic effect on IBS. Compared with the commonly used therapeutic drug mesalazine, *Brutella brevis* MW-022 shows superior improvement effects on multiple indicators.

[0024] Furthermore, *Brutella vesicae* MW-022, isolated from the feces of healthy humans, belongs to the family Lachnospiraceae, a core symbiotic group of the human gut microbiota, and is generally considered non-pathogenic and non-allergenic. Therefore, the *Brutella vesicae* MW-022 provided by this invention possesses high safety, no significant toxic side effects, and is suitable for long-term microecological intervention therapy for irritable bowel syndrome.

[0025] Biological material deposit: Blautia wexlerae MW-022 (i.e. Blautia wexlerae NSP013 in the deposit certificate), classified as Blautia wexlerae, was deposited on September 9, 2025 at the Guangdong Provincial Center for Microbial Culture Collection, located at: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Guangdong Academy of Sciences, Institute of Microbiology, Guangdong Province, with accession number GDMCC No: 66940. Attached Figure Description

[0026] Figure 1 shows the changes in body weight during the experimental intervention; Figure 2 shows the time to the first loose stool during the experimental intervention; Figure 3 shows the mRNA expression level of visceral sensitivity factors; Figure 4 shows the level of inflammatory factors in colon tissue; Figure 5 shows the expression level of MDA and the activity level of MPO in colon tissue; Figure 6 shows the trajectory and quantification of the open field experiment. Detailed Implementation

[0027] This invention provides a bacterial agent for treating irritable bowel syndrome, namely, a bacterial agent of *Blautia wexlerae* MW-022. *Blautia wexlerae* is deposited at the Guangdong Provincial Microbial Culture Collection Center, with accession number GDMCC No: 66940. *Blautia wexlerae* MW-022 is *Blautia wexlerae* NSP013 as stated in the accession certificate. The preparation of the bacterial culture of *Blautia wexlerae* MW-022 includes the following steps: *Blautia wexlerae* MW-022 is inoculated onto YCFA solid medium. After the growth of round, white individual colonies, a single colony is picked and cultured in liquid medium. After 16S rRNA identification and sequence alignment confirming it as *Blautia wexlerae*, the bacterial culture concentration is adjusted to 1×10⁻⁶. 5 ~10 10 CFU / mL. The YCFA liquid culture medium described in this invention is a commercially available product well-known in the art.

[0028] This invention relates to the use of *Brutella brevis* MW-022 in the preparation of medicaments for the prevention or treatment of irritable bowel syndrome (IBS). *Brutella brevis* MW-022, isolated from the feces of healthy humans, belongs to the Lachnospiraceae family, a core symbiotic group of the human gut. It possesses natural compatibility with the host's intestinal environment, is non-pathogenic and non-allergenic, exhibits high safety, and is suitable for use as a probiotic. Experimental results show that *Brutella brevis* MW-022 can effectively slow weight loss, improve bowel abnormalities, reduce visceral hypersensitivity, inhibit low-grade intestinal inflammation, regulate oxidative stress, and alleviate accompanying emotional symptoms, thereby exerting a comprehensive therapeutic effect on IBS. Compared with the commonly used drug mesalazine, *Brutella brevis* MW-022 shows similar or even better therapeutic effects in several aspects, without side effects.

[0029] This invention relates to the use of *Blautia wexlerae* MW-022 in the preparation of medicaments for the prevention or treatment of irritable bowel syndrome (IBS). The strain, isolated from the feces of healthy humans, belongs to the family Lachnospiraceae, a crucial component of the core symbiotic flora of the human gut, involved in host metabolism and immune regulation. *Blautia wexlerae* MW-022 possesses natural compatibility with the gut, is non-pathogenic and non-allergenic, exhibits good safety, and is suitable for development as a probiotic. Experimental studies have confirmed that this strain can significantly improve IBS-related pathological phenotypes, including slowing weight loss, regulating stool frequency and consistency, reducing visceral hypersensitivity, inhibiting low-grade intestinal inflammation, regulating oxidative stress, and alleviating accompanying anxiety-like behaviors and other emotional disturbances. It demonstrates a comprehensive improvement effect on the core symptoms of IBS across multiple key indicators. Compared to the positive control drug mesalazine, *Brutula vesiculosus* MW-022 demonstrated comprehensive efficacy comparable to the drug, with particularly outstanding effects in improving intestinal barrier integrity and alleviating mood disorders. More importantly, its probiotic properties fundamentally avoid the risk of drug side effects, providing a new option that combines efficacy and safety.

[0030] The preferred dosage form of the drug is an oral solid dosage form, including tablets, capsules, granules, microcapsules, or powders; an oral liquid dosage form, including solutions, suspensions, or drops; or a preparation processed by a special process, including lyophilized powder for injection, microcapsules, enteric-coated preparations, or sustained-release preparations; when the dosage form of the drug is an oral liquid, the preferred content of *Brutella brevis* MW-022 in the drug is 1×10⁻⁶. 5 ~1×10 10CFU / mL. Preferably, the drug also includes a pharmaceutically acceptable carrier; the pharmaceutically acceptable carrier preferably includes a dispersion medium, a flow aid, a release regulator, a matrix forming agent, a taste improver, a microbial growth factor, a pH stabilizer, an encapsulating agent, an antioxidant, or a cryoprotectant.

[0031] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0032] Example 1: Screening and Identification of Blautia wexlerae MW-022 Blautia wexlerae MW-022 was isolated from the feces of healthy individuals. After obtaining the feces, it was promptly placed in a strictly anaerobic glove box for subsequent operations. First, a serial dilution was performed, selecting 10... -4 ~10 -8 The concentration was plated on YCFA solid medium and incubated at 37°C under anaerobic conditions for 24 hours. When single colonies were observed to grow, a single colony was picked and streaked onto YCFA solid medium. This process was repeated twice to complete the purification and obtain single bacteria. The bacterial strain was then amplified by PCR and identified. All related operations were performed in a strictly anaerobic glove box.

[0033] Preparation of bacterial culture: Take strain *Brutella westerlens* MW-022 from cryopreservation tubes. When the strain is slightly thawed, pick an appropriate amount of bacteria using a sterile inoculation loop and streak it onto a YCFA agar plate for activation. Incubate at 37°C under anaerobic conditions for 48 hours. After activation, pick a single colony and inoculate it into YCFA liquid medium. Incubate at 37°C under anaerobic conditions for 24 hours. Collect the fermentation broth at the end of the logarithmic phase by centrifugation (4°C, 5000 rpm, 5 min) to collect the bacterial sludge. Wash the bacterial sludge with sterile, anaerobic PBS under the same centrifugation conditions, then resuspend it in sterile, anaerobic PBS. Transfer the resuspended bacterial culture to a vial that has undergone oxygen purging using a syringe. Special note: All operations were performed in a strictly anaerobic glove box. To ensure the viability of the strain, fresh bacterial culture was prepared daily before gavage. In the fermentation and centrifugation resuspension steps of the above-mentioned bacterial suspension, the fermentation volume and dilution factor during bacterial sludge resuspension were determined based on the growth curve of the bacterial strain, so that the viable cell concentration of the obtained bacterial suspension was 1×10⁻⁶. 10 CFU / mL, then take a portion and dilute it with PBS to 1×10⁻⁶. 8 CFU / mL.

[0034] Example 2: Therapeutic effect of *Brutella brevis* MW-022 on irritable bowel syndrome (IBS) 1. Modeling and Grouping Forty-eight 6-week-old (20.0 ± 1.0 g) SPF-grade C57BL / 6J male mice were randomly divided into four groups after one week of acclimatization: normal control group (Group B), model group (Group M), positive drug mesalazine control group (Group AC), and *Brutella brevis* MW-022 intervention group (Group BW). Mice were allowed free access to food and sterilized drinking water for the first 7 days to allow for acclimatization. Modeling began on day 8. Mice in the modeling group were administered a 0.5 g / mL concentration of senna leaf decoction via gavage at a dose of 10 mL / kg. The normal control group received the same amount of PBS via gavage. One hour after gavage, the mice in the modeling group were restrained for one hour using a centrifuge tube fixation method: mice were placed in 50 mL centrifuge tubes with a small opening at the tip, and the tube opening was plugged with foam to restrict their free movement. After unbinding, mice were placed in cages lined with filter paper, and their defecation was observed for 6 hours. The bedding was replaced after 6 hours. During the restraint modeling process, the food was removed from each cage, and replaced daily after the modeling was completed. Model preparation and observation were performed at the same time each day to avoid interference from circadian rhythms. Modeling was conducted throughout the experimental period (days 8-22, considered intervention days 1-15). The intervention period began on day 13 (intervention day 6). Modeling was performed daily at 9:00 AM after weighing the mice. Six hours after modeling, the mice were administered medication (AC group, mesalazine 300 mg / kg by gavage) and *Brutella westermani* MW-022 (BW group, 1×10⁻⁶ mg / kg by gavage). 8 Intervention with CFU / mL bacterial solution was administered once for 10 consecutive days (until day 15 of the intervention period). Intervention was stopped on day 23, and all mice were euthanized by cervical dislocation. Biological samples were collected for subsequent research. During the experiment, changes in mouse weight, time of first defecation, fecal condition, and behavioral experimental results were observed. After the experiment, visceral sensitivity and other indicators were measured, and the success of the model was determined by combining these indicators.

[0035] Table 1 Experimental Group Settings

[0036] 2. Detection methods and results (1) Brontë MW-022 reduced the weight loss of mice with irritable bowel syndrome. The mice were weighed at a fixed time of 9:00 every morning, and the weight change during the 15-day intervention period was recorded.

[0037] As shown in Figure 1, *Brutella vesicae* MW-022 was comparable to mesalazine in inhibiting weight loss. Furthermore, the strain exhibited a unique advantage of more stable weight recovery in the later stages of the experiment. This phenomenon may stem from its effective in vivo colonization and enrichment process, suggesting that this strain has greater potential for long-term treatment.

[0038] (2) During the intervention of MW-022 of *Brutella vegetans* to alleviate the abnormal defecation of mice with irritable bowel syndrome, the mice were placed in a mouse cage lined with filter paper after gavage and unrestraint, and the time of their first defecation of loose stool was recorded.

[0039] According to the experimental results (Figure 2), *Brutella brevis* MW-022 showed a regulatory capacity comparable to mesalazine in delaying the first loose stool passage. On day 14 of intervention, the time to first loose stool passage was prolonged from 12.67 minutes in the model group to 50.67 minutes in the BW group. Although the difference between the normal control group and the *Brutella brevis* MW-022 intervention group was not statistically significant, this trend indicates that this strain has a clear ameliorative effect on the core symptoms of diarrhea-predominant irritable bowel syndrome—defecation urgency and abnormal defecation. More importantly, *Brutella brevis* MW-022 achieved this therapeutic effect while completely avoiding the adverse reactions commonly seen in traditional drugs, demonstrating its unique advantages as a microbial preparation. Therefore, compared to mesalazine, *Brutella brevis* MW-022 has superior safety characteristics while maintaining comparable efficacy, showing greater potential for clinical application.

[0040] (3) Brontë broodie MW-022 reduces visceral sensitivity in mice with irritable bowel syndrome (IBS). IBS patients often experience abdominal discomfort symptoms such as abdominal pain, and the mechanism of its occurrence is closely related to visceral hypersensitivity, which can amplify the transmission of intestinal pain signals. After euthanizing the mice, the prefrontal cortex was harvested to detect the expression levels of visceral sensitivity-related factors calcitonin gene-related peptide (CGRP) and transient receptor potential vanillin subtype 1 (TRPV1).

[0041] According to the experimental results (Figure 3), both mesalazine and *Brutella brevis* MW-022 significantly reduced the expression levels of visceral sensitivity-related factors CGRP and TRPV1 in IBS model mice. *Brutella brevis* MW-022 reduced the mRNA expression level of CGRP from 1.53 in the model group to 0.96, comparable to the control group (1.00); and reduced the mRNA expression level of TRPV1 from 1.13 in the model group to 0.80, close to the control group (0.63). This confirms that both can effectively relieve the core symptom of abdominal pain. The difference between the *Brutella brevis* MW-022 group and the drug group was not statistically significant, indicating that *Brutella brevis* MW-022 is comparable to the drug in its ability to reduce visceral sensitivity. Simultaneously, experimental observations showed that compared with the mesalazine group, the *Brutella brevis* MW-022 group had a lower incidence of pain-related behaviors (such as abdominal contraction and body curling) and significantly improved activity inhibition. Based on its combined advantages in modulating visceral sensitivity and alleviating pain behaviors, *Brutella westermani* MW-022 shows more comprehensive and safer therapeutic potential than traditional drugs.

[0042] (4) Brontë MW-022 inhibits low-grade inflammation in mice with irritable bowel syndrome (IBS). IBS is often accompanied by low-grade intestinal inflammation. To evaluate the effects of different interventions on inflammation, the expression levels of inflammatory factors in the colon tissue of mice were detected after sacrifice.

[0043] The results (Figure 4) showed that, regarding the pro-inflammatory factor TNF-α, both the mesalazine group and the *Brutella brevicella* MW-022 group effectively reduced its expression, with comparable effects. The *Brutella brevicella* MW-022 group showed a more significant decreasing trend, with TNF-α expression in the *Brutella brevicella* MW-022 group decreasing to 134.45 pg / mg compared to the model group (233.99 pg / mg), demonstrating superior efficacy compared to the mesalazine group (159.68 pg / mg). Regarding the anti-inflammatory factor IL-10, both groups showed similar effects, with IL-10 expression in the *Brutella brevicella* MW-022 group increasing to 153.38 pg / mg compared to the model group (113.85 pg / mg). In summary, MW-022 of *Blaubra* also has a synergistic regulatory effect on both pro-inflammatory and anti-inflammatory aspects, which can achieve comprehensive improvement of intestinal inflammation and shows great application potential in the probiotic treatment of irritable bowel syndrome.

[0044] (5) Brontë MW-022 alleviates oxidative stress in mice with irritable bowel syndrome. The pathological process of irritable bowel syndrome is related to increased intestinal oxidative stress. After the mice were sacrificed, the levels of malondialdehyde (MDA) and myeloperoxidase (MPO) in the colon tissue of the mice were detected. The present invention aims to evaluate the efficacy of each intervention in alleviating oxidative stress by detecting the above indicators.

[0045] The results (Figure 5) showed that *Brutella brevis* MW-022 exhibited a significant advantage in improving irritable bowel syndrome-related oxidative stress. Compared with the MDA level (2.19 nmol / mg protein) in the colon tissue of the model group mice, the MDA expression level in the *Brutella brevis* MW-022 group was significantly reduced (0.87 nmol / mg protein), which was better than the control group (1.09 nmol / mg protein) and superior to the mesalazine group (1.48 nmol / mg protein). MPO activity was also effectively inhibited. Compared with the MPO level (1.82 U / g) in the colon tissue of the model group mice, the MPO expression level in the *Brutella brevis* MW-022 group was significantly reduced (0.87 U / g), comparable to the control group (0.85 U / g), and superior to the mesalazine group (1.25 U / g). The improvement in these two key oxidative stress indicators was better than that in the mesalazine control group, and the levels returned to near normal. This result suggests that *Brutella brevis* MW-022 may exert a protective effect on the gut at the molecular level by enhancing the intestinal antioxidant defense system, effectively scavenging excess free radicals, and reducing lipid peroxidation damage. Based on its remarkable effect in regulating oxidative stress, *Brutella brevis* MW-022 shows significant development value and clinical application prospects in the treatment of irritable bowel syndrome.

[0046] (6) *Brutella brevis* MW-022 alleviates affective symptoms in mice with irritable bowel syndrome. An open field test (OFT) was conducted on day 14 of the intervention period. At the start of the experiment, mice were placed in the center of a white open field test chamber (40cm×40cm×60cm), and their activities were recorded for 5 minutes using a camera. After each mouse's test, the open field test chamber was cleaned with 75% alcohol to remove mouse excrement and odor to avoid interference with subsequent mouse tests. Finally, the 5-minute behavioral data recorded for each mouse were analyzed, recording the mouse's movement trajectory and total distance traveled.

[0047] The open field test is a reliable experiment for assessing the behavior and emotional state of mice. Its movement trajectory directly reflects the spontaneous activity, exploratory tendencies, and anxiety-like behaviors of mice. The total movement distance directly characterizes the mouse's basic motor ability and exploratory motivation, and is a key indicator for evaluating behavioral activation levels. The frequency of central area crossing is often used to measure the anxiety level of mice, as anxious mice typically exhibit avoidance tendencies towards open central areas. Combining these two analyses allows for a more effective and comprehensive evaluation of the mouse's mental state. Data showed (Figure 6) that *Brutella brevis* MW-022 was significantly superior to mesalazine in improving anxiety-like behaviors associated with irritable bowel syndrome. The behavioral trajectory plot showed a significant increase in the central area crossing frequency in the *Brutella brevis* MW-022 intervention group, suggesting that their anxiety-like behaviors were more effectively alleviated. Furthermore, compared to the model group mice (1068.64 cm), the total movement distance in the *Brutella brevis* MW-022 group (1829.20 cm) showed a significant improvement comparable to the drug group, recovering to a level close to the control group (2483.29 cm). Therefore, *Brutella brevis* MW-022 demonstrates a more comprehensive therapeutic potential in improving the neuropsychiatric abnormalities associated with irritable bowel syndrome.

[0048] The above data show that when MW-022 of the present invention is used alone to intervene in irritable bowel syndrome (IBS) model mice, the weight loss of IBS mice is slowed, the visceral sensitivity is significantly reduced, the time to first loose stool is delayed, low-grade inflammation is suppressed, oxidative stress is relieved, and emotional disturbances in mice are reduced. It can effectively treat IBS when used alone.

[0049] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A strain of Blautia wexlerae MW-022 has been deposited at the Guangzhou Microbial Culture Collection Center, accession number GDMCC No: 66940.

2. A microbial preparation containing the *Brutella vesicae* MW-022 as described in claim 1.

3. The microbial preparation according to claim 2, characterized in that, In the aforementioned microbial preparation, the bacterial count of *Brutella vesicae* MW-022 is not less than 1 × 10⁻⁶. 5 CFU / mL or 1×10 5 CFU / g.

4. A pharmaceutical product containing the *Brutella vesicae* MW-022 of claim 1 or the microbial preparation of claim 2 or 3.

5. The medicine according to claim 4, characterized in that, The dosage forms of the medicine include solid dosage forms, liquid dosage forms, or semi-solid dosage forms; the solid dosage forms include tablets, capsules, granules, micro-pellets, or powders; the liquid dosage forms include solutions, suspensions, or drops.

6. The pharmaceutical product according to claim 5, characterized in that, The content of *Brutella vesicae* MW-022 in the drug is 1×10⁻⁶. 5 CFU / mL ~ 1×10 10 CFU / mL or 1×10 5 CFU / g ~ 1×10 10 CFU / g.

7. The pharmaceutical product according to claim 6, characterized in that, The drug also includes a pharmaceutically acceptable carrier.

8. The pharmaceutical product according to claim 7, characterized in that, The pharmaceutically acceptable carrier is selected from at least one of the following: dispersion medium, flow aid, release regulator, matrix forming agent, taste improver, microbial growth factor, pH stabilizer, encapsulating agent, antioxidant or cryoprotectant.

9. The use of the *Brutella vesicae* MW-022 of claim 1 or the microbial preparation of claim 2 or 3 in the preparation of a medicament for the prevention and / or treatment of irritable bowel syndrome.

10. The application according to claim 9, characterized in that, The drug has at least one of the following functions: (1) slowing down weight loss; (2) regulating defecation frequency and characteristics; (3) reducing visceral hypersensitivity; (4) inhibiting low-grade intestinal inflammation; (5) regulating oxidative stress; and (6) alleviating anxiety-like behavior.

Images